Total Payments
$27,045
2024 Payments
$9,572
Companies
8
Transactions
35
Medicare Patients
196
Medicare Billing
$57,476
Payment Breakdown by Category
Consulting$12,400 (45.8%)
Research$7,425 (27.5%)
Other$4,500 (16.6%)
Travel$1,715 (6.3%)
Food & Beverage$1,005 (3.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,400 | 4 | 45.8% |
| Unspecified | $7,425 | 2 | 27.5% |
| Honoraria | $4,500 | 1 | 16.6% |
| Travel and Lodging | $1,715 | 4 | 6.3% |
| Food and Beverage | $1,005 | 24 | 3.7% |
Payments by Type
General
$19,620
33 transactions
Research
$7,425
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $9,192 | 9 | $0 (2018) |
| Novartis Pharma AG | $7,525 | 4 | $0 (2018) |
| ABBVIE INC. | $7,523 | 3 | $0 (2024) |
| Sumitomo Pharma America, Inc. | $1,950 | 1 | $0 (2024) |
| Roche TCRC, Inc. | $461.00 | 2 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $209.66 | 10 | $0 (2024) |
| Blueprint Medicines Corporation | $165.37 | 5 | $0 (2024) |
| GlaxoSmithKline, LLC. | $18.75 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,572 | 10 | ABBVIE INC. ($7,425) |
| 2023 | $294.50 | 10 | Novartis Pharmaceuticals Corporation ($164.04) |
| 2018 | $16,717 | 13 | La Jolla Pharmaceutical Company ($9,192) |
| 2017 | $461.00 | 2 | Roche TCRC, Inc. ($461.00) |
All Payment Transactions
35 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $4,125.00 | Research |
| Study: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/00BFRefractory Myelofibrosis (TRANSFORM-2) | ||||||
| 12/26/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $3,300.00 | Research |
| Study: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/00BFRefractory Myelofibrosis (TRANSFORM-2) | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 07/24/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $32.10 | General |
| Category: Oncology / Rare Diseases | ||||||
| 04/15/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $35.99 | General |
| Category: Oncology / Rare Diseases | ||||||
| 03/20/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $32.46 | General |
| Category: Oncology / Rare Diseases | ||||||
| 03/13/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Oncology | ||||||
| 02/14/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $32.28 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/09/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: Oncology | ||||||
| 09/13/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $31.46 | General |
| Category: Oncology | ||||||
| 08/14/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug), TASIGNA | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Oncology | ||||||
| 08/14/2023 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $3.12 | General |
| Category: Oncology | ||||||
| 05/31/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $32.83 | General |
| Category: Oncology | ||||||
| 05/31/2023 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $24.32 | General |
| Category: Oncology | ||||||
| 05/17/2023 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $32.54 | General |
| Category: Oncology / Rare Diseases | ||||||
| 04/03/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $97.92 | General |
| Category: ONCOLOGY | ||||||
| 03/09/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug), TASIGNA | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: Oncology | ||||||
| 02/02/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: Oncology | ||||||
| 11/29/2018 | La Jolla Pharmaceutical Company | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 09/28/2018 | La Jolla Pharmaceutical Company | — | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| 08/22/2018 | La Jolla Pharmaceutical Company | — | Honoraria | Cash or cash equivalent | $4,500.00 | General |
| 08/22/2018 | La Jolla Pharmaceutical Company | — | Food and Beverage | In-kind items and services | $43.00 | General |
| 08/22/2018 | La Jolla Pharmaceutical Company | — | Food and Beverage | In-kind items and services | $33.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/00BFRefractory Myelofibrosis (TRANSFORM-2) | ABBVIE INC. | $7,425 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 68 | 224 | $73,340 | $19,568 |
| 2022 | 1 | 43 | 158 | $48,980 | $13,325 |
| 2021 | 1 | 43 | 183 | $56,730 | $16,530 |
| 2020 | 1 | 42 | 117 | $36,270 | $8,053 |
Total Patients
196
Total Services
682
Medicare Billing
$57,476
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 51 | 194 | $60,140 | $15,796 | 26.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 30 | $13,200 | $3,772 | 28.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 43 | 158 | $48,980 | $13,325 | 27.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 43 | 183 | $56,730 | $16,530 | 29.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 42 | 117 | $36,270 | $8,053 | 22.2% |
About Dr. Ronald Hoffman, M.D
Dr. Ronald Hoffman, M.D is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467558932.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ronald Hoffman, M.D has received a total of $27,045 in payments from pharmaceutical and medical device companies, with $9,572 received in 2024. These payments were reported across 35 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($12,400).
As a Medicare-enrolled provider, Hoffman has provided services to 196 Medicare beneficiaries, totaling 682 services with total Medicare billing of $57,476. Data is available for 4 years (2020–2023), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 09/15/2006
- Last Updated 07/19/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1467558932
Products in Payments
- JAKAVI (Drug) $7,525
- Non-Covered Product (Drug) $461.00
- AYVAKIT (Drug) $165.37
- SCEMBLIX (Drug) $98.05
- VENCLEXTA (Drug) $97.92
- PROMACTA (Drug) $84.17
- TASIGNA (Drug) $27.44
- OJJAARA (Drug) $18.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205